newsfilter
← Latest News
GlobeNewswire·

Selecta Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

– U.S. Food and Drug Administration ("FDA") removed clinical hold on SEL-302 for the treatment of patients with methylmalonic acidemia ("MMA")- -Observed the synergy of ImmTOR in combination with engineered Treg-selective IL-2 to expand antigen-